However, even in one type of cancers, e.g., NSCLC, the impact of c-MET copy number on prognosis is a histological subtype dependent: c-MET amplification with a poorer prognosis in patients with adenocarcinoma but not in those with squamous cell carcinoma [21, 22]. The gene discussed is MET; the disease is cancer.